Anzeige
Mehr »
Sonntag, 19.04.2026 - Börsentäglich über 12.000 News
China - das Pentagon - und dieses Unternehmen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1LG | ISIN: IL0011224156 | Ticker-Symbol:
NASDAQ
17.04.26 | 21:57
0,350 US-Dollar
+0,55 % +0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ICECURE MEDICAL LTD Chart 1 Jahr
5-Tage-Chart
ICECURE MEDICAL LTD 5-Tage-Chart

Aktuelle News zur ICECURE MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.04.IceCure Medical Ltd. - F-1, Registration statement for certain foreign private issuers-
26.03.IceCure prices $4M direct offering, concurrent private placement2
25.03.IceCure Medical Reports Positive Trial Results For ProSense Cryoablation System2
24.03.IceCure Medical: IceCure Appoints Meir Peleg as Chief Financial Officer168Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companiesIceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel...
► Artikel lesen
24.03.IceCure Medical Appoints Meir Peleg As CFO; Shares Rise In Pre-market-
24.03.IceCure Medical Ltd. - 6-K, Report of foreign issuer1
17.03.IceCure Medical: IceCure Reports 2025 Full Year Financial & Operational Results343Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectively Strong commercial momentum for ProSense® in the U.S. and globally following...
► Artikel lesen
17.03.IceCure Medical Ltd Profit Drops In Full Year-
ICECURE MEDICAL Aktie jetzt für 0€ handeln
17.03.IceCure Medical GAAP EPS of -$0.24, revenue of $3.38M2
17.03.IceCure Medical Ltd. - 20-F, Annual and transition report of foreign private issuers-
11.03.IceCure Medical: U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense Cryoablation in the Local Treatment of Low-Risk Breast Cancer324IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense® Clinical...
► Artikel lesen
11.03.IceCure Medical Ltd. - 6-K, Report of foreign issuer-
02.03.IceCure Medical Ltd. - 6-K, Report of foreign issuer3
02.03.IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas221Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation Findings may impact treatment guidelines issued by medical...
► Artikel lesen
24.02.ICCM says government policy has tightened the metals cycle1
23.02.IceCure Medical Ltd. - 6-K, Report of foreign issuer2
23.02.IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026131Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate Incidence...
► Artikel lesen
09.02.IceCure Medical Ltd. - 6-K, Report of foreign issuer2
09.02.IceCure CFO Ronen Tsimerman to depart1
09.02.IceCure Medical: IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved379Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure"...
► Artikel lesen
Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1